Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by houbahopon Mar 30, 2020 7:20pm

116 Views

Post# 30862202

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Weekly Sales Update

It varies from young group ages to older ages. From 0.05% to 15% for the oldest.

But we can't divide today's mortality number to number of cases.
A new positive case caught the virus 10 days before receiving the result in average.

Number of positive cases doubles every 3 days (2.5 in the US).

So today's number of positive is at least 4 times the official number.
And it might be much more but I have not figured out the number tested vs number that will never be tested.

Any thing on this, someone?

Bullboard Posts

Sirios Resource discovers visible gold in Quebec